Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA-XFSC
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
SNA-XFSC is a micro-immunotherapy agent developed by Labo'Life Belgium, specifically designed for the treatment of Epstein-Barr virus (EBV) infections. It is a preparation of specific nucleic acids (SNA) targeting the Epstein-Barr virus genome as well as HLA Class I and HLA Class II sequences. Produced through a high-dilution process, these nucleic acids are intended to modulate the host's immune response and potentially interfere with viral replication. SNA-XFSC is typically administered sublingually in the form of globules, which are designed to be absorbed by the oral mucosa to interact with the lymphatic system. While it has been studied as a standalone intervention in clinical trials, it also serves as the nucleic acid component of the broader micro-immunotherapy product 2LEBV, which additionally contains low-dose cytokines.
- Other names
- SNA-EBV
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on SNA-XFSC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA-XFSC.